Antiretroviral drug-related liver mortality among HIV-positive persons in the absence of hepatitis B or C virus coinfection: the data collection on adverse events of anti-HIV drugs study

Helen Kovari; Caroline A Sabin; Bruno Ledergerber; Lene Ryom Nielsen; Signe W Worm; Colette Smith; Andrew Phillips; Peter Reiss; Eric Fontas; Kathy Petoumenos; Stéphane De Wit; Philippe Morlat; Jens D Lundgren; Rainer Weber

doi:10.1093/cid/cis919

Antiretroviral drug-related liver mortality among HIV-positive persons in the absence of hepatitis B or C virus coinfection: the data collection on adverse events of anti-HIV drugs study

Helen Kovari, Caroline A Sabin, Bruno Ledergerber, Lene Ryom Nielsen, Signe W Worm, Colette Smith, Andrew Phillips, Peter Reiss, Eric Fontas, Kathy Petoumenos, Stéphane De Wit, Philippe Morlat, Jens D Lundgren, Rainer Weber

Department of Immunology and Microbiology

34 Citations (Scopus)

Abstract

Background. Liver diseases are the leading causes of death in human immunodeficiency virus (HIV)-positive persons since the widespread use of combination antiretroviral treatment (cART). Most of these deaths are due to hepatitis C (HCV) or B (HBV) virus coinfections. Little is known about other causes. Prolonged exposure to some antiretroviral drugs might increase hepatic mortality. Methods. All patients in the Data Collection on Adverse Events of Anti-HIV Drugs study without HCV or HBV coinfection were prospectively followed from date of entry until death or last follow-up. In patients with liver-related death, clinical charts were reviewed using a structured questionnaire.Results. We followed 22 910 participants without hepatitis virus coinfection for 114 478 person-years. There were 12 liver-related deaths (incidence, 0.10/1000 person-years); 7 due to severe alcohol use and 5 due to established ART-related toxicity. The rate of ART-related deaths in treatment-experienced persons was 0.04/1000 person-years (95% confidence interval,. 01,. 10). Conclusions. We found a low incidence of liver-related deaths in HIV-infected persons without HCV or HBV coinfection. Liver-related mortality because of ART-related toxicity was rare.

Original language	English
Journal	Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Volume	56
Issue number	6
Pages (from-to)	870-9
Number of pages	10
DOIs	https://doi.org/10.1093/cid/cis919
Publication status	Published - 15 Mar 2013

Keywords

Adult
Anti-Retroviral Agents
Antiretroviral Therapy, Highly Active
Data Collection
Drug-Related Side Effects and Adverse Reactions
Female
Follow-Up Studies
HIV Infections
Humans
Incidence
Liver Failure
Male
Middle Aged
Prospective Studies
Survival Analysis

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1093/cid/cis919

Cite this

Kovari, H., Sabin, C. A., Ledergerber, B., Nielsen, L. R., Worm, S. W., Smith, C., Phillips, A., Reiss, P., Fontas, E., Petoumenos, K., De Wit, S., Morlat, P., Lundgren, J. D., & Weber, R. (2013). Antiretroviral drug-related liver mortality among HIV-positive persons in the absence of hepatitis B or C virus coinfection: the data collection on adverse events of anti-HIV drugs study. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 56(6), 870-9. https://doi.org/10.1093/cid/cis919

Antiretroviral drug-related liver mortality among HIV-positive persons in the absence of hepatitis B or C virus coinfection : the data collection on adverse events of anti-HIV drugs study. / Kovari, Helen; Sabin, Caroline A; Ledergerber, Bruno et al.

In: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, Vol. 56, No. 6, 15.03.2013, p. 870-9.

Research output: Contribution to journal › Journal article › Research › peer-review

Kovari, H, Sabin, CA, Ledergerber, B, Nielsen, LR, Worm, SW, Smith, C, Phillips, A, Reiss, P, Fontas, E, Petoumenos, K, De Wit, S, Morlat, P, Lundgren, JD & Weber, R 2013, 'Antiretroviral drug-related liver mortality among HIV-positive persons in the absence of hepatitis B or C virus coinfection: the data collection on adverse events of anti-HIV drugs study', Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, vol. 56, no. 6, pp. 870-9. https://doi.org/10.1093/cid/cis919

Kovari H, Sabin CA, Ledergerber B, Nielsen LR, Worm SW, Smith C et al. Antiretroviral drug-related liver mortality among HIV-positive persons in the absence of hepatitis B or C virus coinfection: the data collection on adverse events of anti-HIV drugs study. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2013 Mar 15;56(6):870-9. doi: 10.1093/cid/cis919

Kovari, Helen ; Sabin, Caroline A ; Ledergerber, Bruno et al. / Antiretroviral drug-related liver mortality among HIV-positive persons in the absence of hepatitis B or C virus coinfection : the data collection on adverse events of anti-HIV drugs study. In: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2013 ; Vol. 56, No. 6. pp. 870-9.

@article{2a77d8df2c2145dbac86d799136a50b6,

title = "Antiretroviral drug-related liver mortality among HIV-positive persons in the absence of hepatitis B or C virus coinfection: the data collection on adverse events of anti-HIV drugs study",

abstract = "Background. Liver diseases are the leading causes of death in human immunodeficiency virus (HIV)-positive persons since the widespread use of combination antiretroviral treatment (cART). Most of these deaths are due to hepatitis C (HCV) or B (HBV) virus coinfections. Little is known about other causes. Prolonged exposure to some antiretroviral drugs might increase hepatic mortality. Methods. All patients in the Data Collection on Adverse Events of Anti-HIV Drugs study without HCV or HBV coinfection were prospectively followed from date of entry until death or last follow-up. In patients with liver-related death, clinical charts were reviewed using a structured questionnaire.Results. We followed 22 910 participants without hepatitis virus coinfection for 114 478 person-years. There were 12 liver-related deaths (incidence, 0.10/1000 person-years); 7 due to severe alcohol use and 5 due to established ART-related toxicity. The rate of ART-related deaths in treatment-experienced persons was 0.04/1000 person-years (95% confidence interval,. 01,. 10). Conclusions. We found a low incidence of liver-related deaths in HIV-infected persons without HCV or HBV coinfection. Liver-related mortality because of ART-related toxicity was rare.",

keywords = "Adult, Anti-Retroviral Agents, Antiretroviral Therapy, Highly Active, Data Collection, Drug-Related Side Effects and Adverse Reactions, Female, Follow-Up Studies, HIV Infections, Humans, Incidence, Liver Failure, Male, Middle Aged, Prospective Studies, Survival Analysis",

author = "Helen Kovari and Sabin, {Caroline A} and Bruno Ledergerber and Nielsen, {Lene Ryom} and Worm, {Signe W} and Colette Smith and Andrew Phillips and Peter Reiss and Eric Fontas and Kathy Petoumenos and {De Wit}, St{\'e}phane and Philippe Morlat and Lundgren, {Jens D} and Rainer Weber",

year = "2013",

month = mar,

day = "15",

doi = "10.1093/cid/cis919",

language = "English",

volume = "56",

pages = "870--9",

journal = "Clinical Infectious Diseases",

issn = "1058-4838",

publisher = "Oxford University Press",

number = "6",

}

TY - JOUR

T1 - Antiretroviral drug-related liver mortality among HIV-positive persons in the absence of hepatitis B or C virus coinfection

T2 - the data collection on adverse events of anti-HIV drugs study

AU - Kovari, Helen

AU - Sabin, Caroline A

AU - Ledergerber, Bruno

AU - Nielsen, Lene Ryom

AU - Worm, Signe W

AU - Smith, Colette

AU - Phillips, Andrew

AU - Reiss, Peter

AU - Fontas, Eric

AU - Petoumenos, Kathy

AU - De Wit, Stéphane

AU - Morlat, Philippe

AU - Lundgren, Jens D

AU - Weber, Rainer

PY - 2013/3/15

Y1 - 2013/3/15

N2 - Background. Liver diseases are the leading causes of death in human immunodeficiency virus (HIV)-positive persons since the widespread use of combination antiretroviral treatment (cART). Most of these deaths are due to hepatitis C (HCV) or B (HBV) virus coinfections. Little is known about other causes. Prolonged exposure to some antiretroviral drugs might increase hepatic mortality. Methods. All patients in the Data Collection on Adverse Events of Anti-HIV Drugs study without HCV or HBV coinfection were prospectively followed from date of entry until death or last follow-up. In patients with liver-related death, clinical charts were reviewed using a structured questionnaire.Results. We followed 22 910 participants without hepatitis virus coinfection for 114 478 person-years. There were 12 liver-related deaths (incidence, 0.10/1000 person-years); 7 due to severe alcohol use and 5 due to established ART-related toxicity. The rate of ART-related deaths in treatment-experienced persons was 0.04/1000 person-years (95% confidence interval,. 01,. 10). Conclusions. We found a low incidence of liver-related deaths in HIV-infected persons without HCV or HBV coinfection. Liver-related mortality because of ART-related toxicity was rare.

AB - Background. Liver diseases are the leading causes of death in human immunodeficiency virus (HIV)-positive persons since the widespread use of combination antiretroviral treatment (cART). Most of these deaths are due to hepatitis C (HCV) or B (HBV) virus coinfections. Little is known about other causes. Prolonged exposure to some antiretroviral drugs might increase hepatic mortality. Methods. All patients in the Data Collection on Adverse Events of Anti-HIV Drugs study without HCV or HBV coinfection were prospectively followed from date of entry until death or last follow-up. In patients with liver-related death, clinical charts were reviewed using a structured questionnaire.Results. We followed 22 910 participants without hepatitis virus coinfection for 114 478 person-years. There were 12 liver-related deaths (incidence, 0.10/1000 person-years); 7 due to severe alcohol use and 5 due to established ART-related toxicity. The rate of ART-related deaths in treatment-experienced persons was 0.04/1000 person-years (95% confidence interval,. 01,. 10). Conclusions. We found a low incidence of liver-related deaths in HIV-infected persons without HCV or HBV coinfection. Liver-related mortality because of ART-related toxicity was rare.

KW - Adult

KW - Anti-Retroviral Agents

KW - Antiretroviral Therapy, Highly Active

KW - Data Collection

KW - Drug-Related Side Effects and Adverse Reactions

KW - Female

KW - Follow-Up Studies

KW - HIV Infections

KW - Humans

KW - Incidence

KW - Liver Failure

KW - Male

KW - Middle Aged

KW - Prospective Studies

KW - Survival Analysis

U2 - 10.1093/cid/cis919

DO - 10.1093/cid/cis919

M3 - Journal article

C2 - 23090925

SN - 1058-4838

VL - 56

SP - 870

EP - 879

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

IS - 6

ER -

Antiretroviral drug-related liver mortality among HIV-positive persons in the absence of hepatitis B or C virus coinfection: the data collection on adverse events of anti-HIV drugs study

Abstract

Keywords

UN SDGs

Access to Document

Fingerprint

Cite this